Nikola’s 2025 upside case relies heavily on hydrogen technology cost curve declines. Breakthroughs on fuel cell efficiency could narrow losses, paving the path for the share price to test $4.50 levels in optimistic scenarios. Biotech stock Lexicon Pharmaceuticals (NASDAQ: LXRX) is another of the fastest-growing stocks on the planet in 2024. After producing an estimated $3.8 million in sales in 2023, Wall Street analysts collectively believe it'll near $46 million in revenue this year. While the RSI of 28 indicates the stock is undervalued (and it did bring in a record $31 million in revenue in Q2 2024), poor performance and constantly negative headlines will likely keep NKLA shares in the basement for the rest of the year. Market trends suggest Nikola’s 2025 performance will be influenced by shifting regulatory incentives for zero-emission trucks. Forecast models point to a base case of $2.90 per share, contingent on achieving quarterly deliveries above 400 units.